16:10 , Jul 24, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Patient sample and mouse studies suggest a factor H-CR2 conjugate that inhibits C3d deposition could help treat stroke. In postmortem brain samples from three patients, deposition of C3d was higher in the perilesional area...
19:30 , Jun 15, 2018 |  BC Week In Review  |  Company News

ChemoCentryx, Vifor Fresenius expand CCX140, avocapan deal to include China

ChemoCentryx Inc. (NASDAQ:CCXI) granted Vifor Fresenius Medical Care Renal Pharma Ltd. exclusive rights to commercialize avacopan (CCX168) and CCX140 in China under the second expansion of a 2016 deal. Vifor Fresenius gained exclusive commercialization rights...
18:48 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Cell culture and mouse studies suggest an ANXA5-targeting, single-chain variable fragment (scFv)-based fusion protein could help treat stroke. The protein consists of an scFv derived from a mouse IgM antibody targeting ANXA5, which is...
15:47 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Circulating plasmablast and B cell numbers could help predict the risk of high-grade, immune-related adverse events in melanoma patients treated with anti-CTLA-4/anti-PD-1 antibody combinations. In peripheral blood mononuclear cells (PBMCs) from 23 patients...
00:44 , Jan 5, 2018 |  BC Extra  |  Company News

ChemoCentryx gains after EMA validates avacopan MAA

ChemoCentryx Inc. (NASDAQ:CCXI) jumped $2.44 (39%) to $8.63 Thursday after it said EMA validated an MAA for avacopan (CCX168), triggering a $50 million milestone payment from Vifor Fresenius Medical Care Renal Pharma Ltd. ChemoCentryx also...
22:23 , Aug 11, 2017 |  BioCentury  |  Regulation

Foundation for inclusion

Hosting a patient-focused drug development workshop was the National Kidney Foundation Inc.’s first step in assuming the role of facilitator to collect patient perspectives that will shape R&D for kidney disease. On Aug. 4, the advocacy...
01:06 , Aug 4, 2017 |  BC Extra  |  Politics & Policy

National Kidney Foundation holding patient-focused meeting with FDA

On Friday, the National Kidney Foundation (NKF) will lead a patient-focused drug development (PFDD) meeting on complement 3 glomerulopathy (C3G), a rare kidney disease, in the hopes of advancing development of innovative treatments for the...
00:27 , Jul 21, 2017 |  BC Week In Review  |  Clinical News

Biothera begins Phase Ib/II trial of Imprime PGG plus Keytruda in NSCLC

Biothera Pharmaceuticals Inc. (Eagan, Minn.) began an open-label, U.S. Phase Ib/II trial to evaluate IV Imprime PGG plus IV Keytruda pembrolizumab in up to 36 patients with non-small cell lung cancer (NSCLC) whose cancer worsened...
23:20 , Jul 11, 2017 |  BioCentury  |  Emerging Company Profile

Complementary ALS play

Alsonex Pty. Ltd. is targeting a central component of the complement cascade to quell neuroinflammation in amyotrophic lateral sclerosis without excessively dampening the immune system. That mechanism could slow disease progression and improve life expectancy...
21:00 , Jun 22, 2017 |  BC Innovations  |  Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...